Dr. Evan K. Harmon, MD
Interventional Cardiology (Interventional Cardiology Physician)
At a glance
- Medical school
- University of North Carolina at Chapel Hill School of Medicine (2018)
- Years since graduation
- 8
- In the NPI registry since
- 2018
Licensed in Alabama since 2025, according to the Alabama Board of Medical Examiners and Medical Licensure Commission. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is
Education and training
- 2018Medical school: University of North Carolina at Chapel Hill School of Medicine
- 2018Registered with an NPI (national billing number; not a license date)
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Interventional Cardiology Physician primary
AL license 52910 (first issued 2025; active) -
Cardiovascular Disease Physician
AL license 52910 (first issued 2025; active)
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Cleveland Clinic Cleveland, OH
- Springhill Medical Center Mobile, AL
Medical groups
- Cardiology Associates of Mobile Inc (54 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Clopidogrel (clopidogrel bisulfate) Other prescribers in Mobile, AL | 44 |
| Isosorbide Mononitrate Er (isosorbide mononitrate) Other prescribers in Mobile, AL | 12 |
| Atorvastatin Calcium Other prescribers in Mobile, AL | 11 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 7 companies reported 21 payments worth $1,683 in total to this clinician.
| Medtronic, Inc. | $694 |
|---|---|
| Edwards Lifesciences Corporation | $388 |
| Abbott Laboratories | $380 |
| Boston Scientific Corporation | $151 |
| Philips North America LLC | $32.00 |
| Abiomed | $22.59 |
| Terumo Medical Corporation | $15.78 |
| Food and Beverage | $1,500 |
|---|---|
| Education | $183 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Medtronic, Inc. Feb 26, 2025 | Education RESOLUTE ONYX · Stents · in-kind | $183 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $3,247 in research payments for these studies, mostly to the institutions running them.
- A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes
Eli Lilly and Company · Completed · NCT04255433
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.